Cowen & Co. Downgrades Graphite Bio to Market Perform
Cowen & Co. analyst Phil Nadeau downgrades Graphite Bio (NASDAQ:GRPH) from Outperform to Market Perform.
Morgan Stanley Maintains Equal-Weight on Graphite Bio, Lowers Price Target to $3
Morgan Stanley analyst Jeffrey Hung maintains Graphite Bio (NASDAQ:GRPH) with a Equal-Weight and lowers the price target from $6 to $3.
Expert Ratings for Graphite Bio
Analysts have provided the following ratings for Graphite Bio (NASDAQ:GRPH) within the last quarter: Bullish Somewhat Bullish Indifferent…
B of A Securities Downgrades Graphite Bio to Neutral, Lowers Price Target to $3
B of A Securities analyst Geoff Meacham downgrades Graphite Bio (NASDAQ:GRPH) from Buy to Neutral and lowers the price target from $7 to $3.
Looking Into Graphite Bio’s Recent Short Interest
Graphite Bio's (NASDAQ:GRPH) short percent of float has fallen 3.92% since its last report. The company recently reported that it has 1.25 million shares sold short, which is 5.64% of all regular shares that are available for trading.
Dow Jumps 700 Points; S&P 500 Rises Over 2%
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 700 points on Friday.
Nasdaq Gains 1.5%; Fate Therapeutics Shares Plunge
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 550 points on Friday.
Benzinga’s Top Ratings Upgrades, Downgrades For January 6, 2023
Upgrades Piper Sandler upgraded the previous rating for Aligos Therapeutics Inc (NASDAQ:ALGS) from Neutral to Overweight. Aligos Therapeutics…
Why Graphite Bio Shares Are Trading Lower By 50%; Here Are 20 Stocks Moving Premarket
Gainers
OncoCyte Corporation (NASDAQ: OCX) rose 89.2% to $0.70 in pre-market trading. Oncocyte, last month, announced an over 40% reduction of its workforce to realign the team towards key products that address larger markets.
BMO Capital Downgrades Graphite Bio to Market Perform, Lowers Price Target to $7
BMO Capital analyst Kostas Biliouris downgrades Graphite Bio (NASDAQ:GRPH) from Outperform to Market Perform and lowers the price target from $14 to $7.